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Phagocytosis of apoptotic cells (efferocytosis) induces macrophage differentiation towards a regulatory phenotype (IL-10high/IL-
12p40low). CD36 is involved in the recognition of apoptotic cells (AC), andwe have shown that the platelet-activating factor receptor
(PAFR) is also involved. Here, we investigated the contribution of PAFR and CD36 to efferocytosis and to the establishment of a
regulatory macrophage phenotype. Mice bone marrow-derived macrophages were cocultured with apoptotic thymocytes, and the
phagocytic indexwas determined. Blockage of PAFRwith antagonists orCD36with specific antibodies inhibited the phagocytosis of
AC (∼70–80%). Using immunoprecipitation and confocal microscopy, we showed that efferocytosis increased the CD36 and PAFR
colocalisation in the macrophage plasma membrane; PAFR and CD36 coimmunoprecipitated with flotillin-1, a constitutive lipid
raft protein, and disruption of these membrane microdomains by methyl-𝛽-cyclodextrin reduced AC phagocytosis. Efferocytosis
induced a pattern of cytokine production, IL-10high/IL-12p40low, that is, characteristic of a regulatory phenotype. LPS potentiated the
efferocytosis-induced production of IL-10, and this was prevented by blocking PAFRorCD36. It can be concluded that phagocytosis
of apoptotic cells engages CD36 and PAFR, possibly in lipid rafts, and this is required for optimal efferocytosis and the establishment
of the macrophage regulatory phenotype.
1. Introduction
Clearance of apoptotic cells (AC) bymacrophages, also called
efferocytosis, plays a central role in tissue homeostasis, and
the impaired clearance of altered cells has been associated
with the development of autoimmune and chronic inflam-
matory diseases [1].Macrophages can acquire distinct pheno-
types depending on the stimulus. M1 or classically activated
macrophages are induced by the recognition of PAMPs
(pathogen associated molecular patterns) and by proinflam-
matory cytokines.These cells exhibit highmicrobicidal activ-
ity and induce inflammation. In contrast, M2 macrophages
produce anti-inflammatory and tissue remodelling cytokines
and can be divided into subtypes according to the stimulus;
the alternatively activated macrophages are induced by Th2
cytokines, and the regulatory macrophages are induced by
anti-inflammatory cytokines, immune complexes, apoptotic
cells, and oxidised lipids, among other stimuli [2, 3].
The first evidence that efferocytosis induces a suppressor
phenotype came from the studies of Fadok et al. [4]. The
authors showed that the addition of apoptotic cells to macro-
phages inhibited the expression of proinflammatory cytok-
ines induced by LPS. Later on, it was reported that the clear-
ance of apoptotic neutrophils induced an IL-10high/IL-12low
regulatory phenotype in macrophages [5].
There is evidence that platelet-activating factor (PAF) or
PAF-like moieties present in the tumour microenvironment
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promote tumour growth by suppressing macrophage func-
tions [6]. The addition of apoptotic cells to a subtumorigenic
dose of melanoma cells promoted tumour growth, and this
phenomenon was significantly reduced when an antagonist
of the PAF receptor (PAFR) was injected into the tumour site
[7]. Also, phagocytosis of AC has been shown to be decreased
by the pretreatment of macrophages with antagonists of
PAFR [8]. Moreover, PAFR was shown to be involved in
the systemic immunosuppression induced by environmental
stressor agents, such as UV radiation and cigarette smoke
[9, 10].
The membrane of AC exhibits oxidised phospholipids,
which are not present in viable cells. Macrophages recognise
these modified lipids through a group of receptors known
as “scavenger receptors” [11]. It is well established that
CD36 is one of the main “scavenger” receptors involved in
the recognition of modified lipids, including oxidised LDL
(oxLDL) [11, 12]. We showed cross-desensitisation between
oxLDL and PAF [8] and that engagement of both CD36 and
PAFR is required for the optimal uptake of oxLDL [13, 14].
In the present study, we investigated the contribution of each
receptor for phagocytosis of AC and for the induction of
a regulatory phenotype (IL-10high/IL-12p40low) in murine
bone marrow-derived macrophages.
2. Materials and Methods
2.1. Cell Culture. Male, 6–8-week-old C57BL/6 mice were
obtained from our own animal facilities and were housed
in a 12 h light/dark cycle room with water and food ad
libitum. Animal care and research protocols were in accor-
dance with the principles and guidelines adopted by the
Brazilian College of Animal Experimentation (COBEA) and
approved by the Biomedical Sciences Institute/USP-Ethical
Committee for Animal Research (CEEA). Bone marrow-
derived macrophages (BMDM) were obtained as previously
described by Davies and Gordon [15], with minor modifica-
tions. In brief, femurs were flushed with DMEM (Dulbecco’s
modified eagle medium containing 2mM l-glutamine,
100U/mLpenicillinG, and 100mg/mL streptomycin, all from
Gibco, Long Island, NY, USA), using a 26-G x 1/2󸀠󸀠 needle.
Cells were grown in DMEM containing 20% LCM (L-929
cell conditioned medium) and 15% of heat-inactivated foetal
calf serum (FCS), incubated at 37∘C in 5% CO
2
. On day 3,
new fresh DMEM with LCM was added. A monolayer of
macrophages was scraped on day 6 (96% of the cells were
positive for CD11b and F4/80). Macrophages were cultured
in DMEM with 5% FCS for one day before the experiments.
2.2. Induction of Apoptosis. Apoptosis of thymocytes was per-
formed as described previously [16]. Briefly, thymuses from
young (5-6 weeks old) male C57BL/6 mice were harvested
and macerated. A suspension of thymocytes at a concen-
tration of 1 × 106 cells/mL was incubated with 1 𝜇M of dex-
amethasone (Sigma-Aldrich, St. Louis, MO, USA) for 6 h in
DMEM with 10% FCS. Before addition to the macrophages,
apoptotic thymocytes were washed three times for the
removal of dexamethasone.
2.3. Cell Treatment. The blockage of PAFR was performed
using the chemically unrelated antagonists WEB (WEB2086
from Tocris, Bristol, UK) and CV (CV3988 from Enzo
Lifesciences, Farmingdale, NY, USA), which were added
to macrophages 30min prior to the addition of apoptotic
cells. The concentration of WEB (50𝜇M) and CV (10 𝜇M)
used here was based on previous works by our group [8,
17]. CD36 was blocked by a specific anti-CD36 blocking
antibody (monoclonal IgA anti-CD36, clone CRF D-2712,
BD Biosciences, Franklin Lakes, NJ, USA) at 1 𝜇g/mL, added
30min before the addition of AC.The disruption of lipid rafts
was performed by depleting cholesterol from membranes
with 1mMmethyl-𝛽-cyclodextrin (𝛽CD) or with the inactive
analogue 𝛼-cyclodextrin (𝛼CD) (all from Sigma-Aldrich, St.
Louis, MO, USA) 10min prior to AC.
2.4. Phagocytosis of Apoptotic Cells. To determine the phago-
cytic index, macrophages were allowed to adhere to glass
coverslips inside 24-well culture microplates. On the next
day, nonadherent cells were removed, macrophages were
treated with drugs or blocking antibody (WEB, CV, 𝛽CD,
𝛼CD, vehicle or CD36 Ab, and control Ab), and 10 AC
per macrophage were added for phagocytosis for 90min.
The noningested cells were removed and coverslips were
stained with haematoxylin and eosin. Results are expressed
as a phagocytic index, which was derived by multiplying the
percentage of macrophages containing at least one ingested
AC by the number of targets ingested by the macrophages.
2.5. Coimmunoprecipitation and Immunoblotting. Macro-
phages were treated with PAF (10−7M) (Cayman Chemical,
Ann Arbor, Michigan, USA) or apoptotic cells (10 per macro-
phage) for 20min. After washing and resting, activated cells
were lysed without agitation on ice for 30min using HEPES
buffer containing 1mM CaCl
2
, 1 mM MgCl
2
, 1% Triton X-
100, protease inhibitor cocktail (Sigma-Aldrich, St. Louis,
MO, USA), and phosphatase inhibitors (NaF and Na
3
VO
4
(Calbiochem-Merck Chemicals, Nottingham, UK). Lysates
were incubated overnight with the primary antibody of
interest (rabbit anti-PAFR or mouse IgA anti-CD36) at 4∘C
with gentle agitation. Protein A-Sepharose (GE Healthcare,
NJ, USA) and protein G-Sepharose (Amersham-Pharmacia
Biotech, Uppsala, Sweden) were added to samples containing
anti-PAFR or anti-CD36, respectively, and incubated for 3 h
at 4∘C with gentle agitation. Immune complexes bound to
beads were washed three times withHEPES buffer containing
protease and phosphatase inhibitors, without Triton X-100,
and boiled in SDS sample buffer for 5 minutes. Proteins were
separated by 10% SDS-PAGE, transferred to a Hybond nitro-
cellulose membrane (GE Healthcare, NJ, USA), and incu-
bated with rabbit-anti-PAFR (CaymanChemical, AnnArbor,
Michigan, USA), mouse IgA-anti-CD36 (BD Biosciences,
Franklin Lakes, NJ, USA) or mouse anti-flotillin-1 (BD Bio-
sciences, Franklin Lakes, NJ, USA). As secondary antibodies,
we used anti-rabbit IgG-HPR (1 : 2000), anti-mouse-HRP
(1 : 1000) (Cell Signaling Technology, Beverly, MA, USA),
biotin-anti-IgA (1 : 500) (BD Biosciences, Franklin Lakes,
NJ, USA) with streptavidin-HRP (1 : 200) (Life Technologies,
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Carlsbad, CA, USA) and visualised using SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientific, Rock-
ford, IL, USA). The resulting autoradiograms were analysed
with the AlphaEaseFC software V3.2 beta (Alpha Innotech,
San Leandro, CA, USA).
2.6. Confocal Microscopy. Macrophages were plated on glass
cover slips and treated with apoptotic cells (10 per mac-
rophage) for 20 minutes. After gentle washing with PBS,
cells were fixed with 3% paraformaldehyde. Cells were
blocked with 1% BSA in PBS before incubation with primary
antibodies including anti-PAFR (1 : 100) (Cayman Chemical,
Ann Arbor, Michigan, USA) and IgA anti-CD36 (1 : 100)
(BD Biosciences, Franklin Lakes, NJ, USA). Alexa Fluor 647
goat anti-rabbit IgG (1 : 100) (Invitrogen-Life Technologies,
Carlsbad, CA, USA) and biotin-anti-mouse IgA (1 : 200) with
streptavidin-PE (1 : 200) (BD Biosciences, Franklin Lakes,
NJ, USA) were used as secondary antibodies. Cells stained
with secondary antibody and control antibody were used to
control for the background from each fluorophore. Slides
were mounted in Prolong Gold antifade reagent with DAPI
(4,6-diamidino-2-phenylindole) (Invitrogen-Life Technolo-
gies, Carlsbad, CA, USA). Cells were imaged on a Zeiss LSM
510 confocal microscope using the 100x oil objective. Con-
focal images were taken with identical settings to allow the
comparison of staining. Single confocal sections of the cells
were captured in multitrack. Each set of frames from a given
treatment condition depicts a representative from at least 20
analysed cells in three independent experiments. Colocal-
isation was quantified by analysing at least 10 images and
determining Pearson’s coefficient using JACoP (Just Another
Colocalisation Plugin), and the software ImageJ 1.46r (NIH,
USA), which is available at http://imagej.nih.gov/ij/ [18].
Basically, a linear equation is calculated to describe the
relationship between the intensities in two images (separate
colours). The slope of this linear approximation provides
the rate of association of two fluorochromes, and Pearson’s
coefficient estimates the goodness of this approximation [19].
2.7. Cytokine Measurement. Macrophages were treated with
drugs/blocking antibody (WEB, CV, 𝛽CD, 𝛼CD, or CD36Ab,
30min before addition of AC (10 per macrophage)). After
24 h of phagocytosis, one group was stimulated with LPS
(10 ng/mL) for 24 h. The supernatants were centrifuged for
the removal of noningested cells, and levels of IL-10 and IL-
12p40weremeasured using aBDOptEIAkit (BDBiosciences,
San Diego, CA, USA) according to the manufacturer’s speci-
fications.
2.8. Statistical Analysis. Data are presented as mean ± stan-
dard error mean (SEM). Analysis of variance (ANOVA) and
the Student-Newman-Keuls posttest were used to evaluate
the statistical significance of the differences between three
or more groups. A two-tailed unpaired Student’s 𝑡-test was
used when differences between two groups were analysed.
Significance was assumed when 𝑃 < 0.05.
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Figure 1: Efferocytosis involves PAFR and CD36. BMDM plated
on coverslips were treated with PAFR antagonists WEB (WEB2086,
50 𝜇M) or CV (CV3988, 10 𝜇M) alone or in association with a
specific blocking antibody to CD36 (1 𝜇g/mL) for 30min before
addition of apoptotic thymocytes (10 permacrophage). After 90min
of phagocytosis, cells were washed for removal of noningested
targets and coverslips were stained with haematoxylin/eosin. The
phagocytic indexes (derived by multiplying the percentage of
macrophages containing at least one ingested target by the number
of targets ingested by the macrophages) were assessed by cell
counting under an optical microscope. Values are mean ± SEM of
at least three independent experiments ( ∗𝑃 < 0.05 versus control;
∗∗
𝑃 < 0.01 versus control; #𝑃 < 0.05 versus WEB, CV, and CD36
Ab).
3. Results
3.1. Efferocytosis Is Dependent on the Engagement of PAFR and
CD36 . To investigate whether the engagement of both PAFR
and CD36 is required for macrophages to phagocytose AC,
murine macrophages were pretreated with two chemically
unrelated antagonists,WEB2086 andCV3988, andCD36was
blocked by a specific antibody. Figure 1 shows that PAFR
antagonists decreased the phagocytosis of AC (WEB 71% and
CV 79%). Blockage of CD36 also reduced the phagocytosis
of AC (70%). The simultaneous blockage of CD36 and PAFR
was even more effective at inhibiting the phagocytosis of AC
(90 and 93% for association of CD36 with WEB2086 and
CV3988, resp.). These results suggest that both receptors are
involved in the phagocytosis of AC by macrophages.
We then investigated the possibility of physical interac-
tion between these receptors by evaluating whether phago-
cytosis of apoptotic cells induces the coimmunoprecipitation
and colocalisation of CD36 with PAFR. We found that
the addition of AC to macrophages induced the immuno-
precipitation of PAFR and CD36, detected within 20min
(Figure 2(a)). A basal coprecipitation of PAFR and CD36 was
also observed in resting (control) macrophages, which was
not increased after the stimulation of PAFR by the agonist
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Figure 2: Colocalisation of PAFR and CD36 occurs during efferocytosis. BMDMwere treated with PAFR agonist (PAF, 10−7M) or apoptotic
thymocytes (10 permacrophage) for 20min to assess coimmunoprecipitation and colocalisation of PAFR and CD36. After washing, cells were
lysed and subjected to immunoprecipitation and immunoblotting as described in Section 2, using antibodies to CD36 and PAFR (a). Another
group was subjected to fixation prior to staining with anti-PAFR and anti-CD36 primary antibodies, followed by FITC- and PE-labelled
secondary antibodies, respectively, and visualised by confocal microscopy as described in Section 2 (b). Quantification of colocalisation (c)
was performed using Pearson’s coefficient and JACoP/ImageJ software, and data are presented as mean ± SEM of 15 pictures from three
independent experiments ( ∗𝑃 < 0.05 versus vehicle). Protein expression was quantified by the AlphaEaseFC software v3.2 beta (Alpha
Innotech). The autoradiographs show one representative experiment, and graph data are presented as mean ± SEM of three experiments
( ∗𝑃 < 0.05 versus control).
PAF alone. This was reinforced by colocalisation analysis
performed by confocal microscopy. Macrophages incubated
with AC were labelled with antibodies to CD36 (red) and
PAFR (green). We found in AC-treated macrophages, in
contrast to the control and PAF-treated macrophages, that
there was a redistribution of PAFR and CD36, increasing
their colocalisation (2-fold), as shown by the enhanced yellow
spots on the macrophage plasma membrane, visualised in
Figure 2(b) and quantified in Figure 2(c). As the samples
were not permeabilised, the CD36 and PAFR fluorescence
observed reflects the presence of these receptors in the cell
membrane. Based on this, we can conclude that the overlap
of CD36 and PAFR observed in Figure 2(b) occurs on the
cell membrane. These data strongly suggest that AC induces
a spatial redistribution of PAFR and CD36 in the plasma
membrane, resulting in increased immunoprecipitation and
colocalisation of these receptors.
Lipid rafts are specialised microdomains in the plasma
membrane that allow interactions between receptors. To
investigate whether intact lipid rafts are required for the
phagocytosis of AC, the phagocytic index was assessed after
the treatment of macrophages with methyl-𝛽-cyclodextrin
(𝛽CD), which depletes cholesterol from the membrane,
causing a disruption of lipid rafts. We found that the
ingestion of apoptotic cells was reduced after macrophages
were treated with 𝛽CD (Figure 3(a)), unlike macrophages
that were treated with alpha-cyclodextrin (𝛼CD; chemically-
related to 𝛽CD, used as a control with no effect in lipid rafts).
Furthermore, immunoprecipitation assays were performed
for the detection of flotillin-1, which is a protein that is
typically found in lipid rafts [20]. Figure 3(b) shows that, in
macrophages that have ingested apoptotic cells, the amount
of flotillin-1 was significantly increased in the samples
immunoprecipitated with antibodies to CD36. Likewise, in
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Figure 3: Efferocytosis requires lipid raft integrity. BMDM were treated with 𝛽CD (1mM) or 𝛼CD (1mM) for 10min before addition
of apoptotic thymocytes (10 per macrophages) for 90min for phagocytosis. After washing for removal of noningested targets, coverslips
were stained with haematoxylin/eosin and the phagocytic indexes (derived by multiplying the percentage of macrophages containing
at least one ingested target by the number of targets ingested by the macrophages) were assessed by cell counting under an optical
microscope. Values are mean ± SEM of at least three independent experiments ( ∗𝑃 < 0.05 versus control) (a). In parallel, BMDM
were incubated with apoptotic thymocytes (10 per macrophage) for 20min before addition of lysis buffer. Cells lysates were subjected to
immunoprecipitation/immunoblotting assays as described in Section 2 using antibodies to PAFR or CD36 and flotillin-1. Protein expression
was quantified by the AlphaEaseFC software V3.2 beta. The autoradiographs show one representative experiment, and graph data are
presented as mean ± SEM of three experiments ( ∗𝑃 < 0.05) (b).
the samples immunoprecipitated with antibodies to PAFR,
the amount of flotillin-1 was also increased. Together, these
results show that when apoptotic cells interact with macro-
phages, PAFR and CD36 are recruited to the lipid rafts and
that the integrity of these membrane domains is required for
the optimal ingestion of apoptotic cells.
3.2. PAFR and CD36 Contribute to the Induction of a Regula-
tory Phenotype in Macrophages during Efferocytosis. We next
evaluated the phenotype of macrophages that have ingested
AC by measuring the production of IL-12p40 and IL-10.
Figure 4(a) shows that these macrophages produced IL-10
and small amounts of IL-12p40. In order to potentiate the pro-
duction of these cytokines, LPS was added to macrophages
24 h after efferocytosis. In these conditions, the production of
IL-10, increased whereas IL-12p40 was not affected, resulting
in an IL-10high/IL-12low phenotype, which is characteristic
of regulatory macrophages. We then evaluated the effect of
PAFR antagonists, anti-CD36 antibodies, or the combination
of both on cytokine production. Figure 4(b) shows that the
blockage of PAFR or CD36 inhibited efferocytosis-induced
IL-10 production without affecting IL-12p40. In the case
of treatment with the PAFR antagonist CV3988, the IL-
10/IL-12p40 ratio changed from 1.4 in the nontreated to
0.6 in the antagonist-treated macrophages. Blocking CD36
or both PAFR and CD36 had a similar effect, redirecting
macrophages towards a more activated profile by favouring
higher amounts of IL-12p40 relative to IL-10. These results
show that, during efferocytosis, macrophages acquire an IL-
10
high/IL-12p40low cytokine production profile and that both
PAFR and CD36 are involved in the establishment of a
regulatory phenotype in macrophages that have ingested AC.
4. Discussion
Here, we showed that engagement of both PAFR and CD36
is required for the phagocytosis of apoptotic cells and for
the induction of the IL-10high/IL-12p40low profile (regula-
tory) that follows efferocytosis. In addition, we showed that
efferocytosis increased the colocalisation of these receptors
and immunoprecipitation with the membrane lipid raft
marker protein flotillin-1; also we demonstrated that lipid
raft integrity is required for the optimal ingestion of AC.
To our knowledge, this is the first study to suggest that
PAFR and CD36 co-localise and are recruited to lipid raft
microdomains during efferocytosis and that the engagement
of both receptors is required for AC ingestion and the
induction of a regulatory phenotype of macrophages.
Both PAFR and CD36 recognise modified/oxidised lipids
and share common ligands, such as oxLDL and moieties
present in the membrane of apoptotic cells, as shown here.
Recently, we showed that co-stimulation of PAFR and CD36
is required for the uptake of oxLDL and for the induction
of cytokine genes by oxLDL [13, 14]. Here, we showed
that recognition and phagocytosis of apoptotic cells were
also dependent on PAFR and CD36. This was shown by
using two chemically unrelated PAFR antagonists and by
blocking CD36 with a specific antibody. Interestingly, the
simultaneous blockage of both receptors had an additive
effect in efferocytosis inhibition. These results suggest that
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Figure 4: Efferocytosis-induced IL-10 and IL-12p40 production. Apoptotic thymocytes were added to BMDM (10 per macrophage), and after
24 h the supernatants were assayed (a). Another group, after 24 h of contact with apoptotic cells, was stimulated with LPS (10 ng/mL), and
supernatants were assayed after 24. Treatments with PAFR antagonists WEB (WEB2086, 50𝜇M) or CV (CV3988, 10 𝜇M) and with specific
blocking antibody to CD36 (1 𝜇g/mL) were performed 30min prior to the addition of apoptotic thymocytes. IL-10 and IL-12p40 levels in the
cultures supernatants were assessed by ELISA according to manufacturer’s specifications. Data are presented as the mean ± SEM ( ∗𝑃 < 0.05
versus control without AC; #𝑃 < 0.05 versus control with apoptotic cells).
moieties present in the ACmembrane engage both receptors,
and that this is required for the ingestion of AC. Furthermore,
we were able to demonstrate by immunoprecipitation and
confocal microscopy that efferocytosis caused an increase in
CD36 and PAFR colocalisation. Since the samples were not
permeabilised, we can conclude that the overlap of CD36
and PAFR occurs in the cell membrane. However, the pos-
sibility of interactions between receptors in the phagosome
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membrane after apoptotic cell ingestion or even on cytoplas-
mic compartments cannot be ruled out.
The dynamics and trafficking of membrane receptors
involve the formation of lipid rafts (LR), which are choles-
terol- and sphingomyelin-richmembranemicrodomains that
function as platforms to promote the association of signalling
molecules and the compartmentalisation of cellular processes
[21]. It has been shown that CD36 is recruited to lipid rafts
in a ligand-dependent manner [22, 23], and that PAFR
has a binding motif for a constitutive protein of lipid rafts
(caveolin-1) in its sequence [24]. Here, we showed that, dur-
ing efferocytosis, PAFR and CD36 co-immunoprecipitated
with flotillin-1, which is a protein that is typically found in
lipid rafts and is used as a protein marker to detect these
microdomains. When LR were disrupted by cholesterol with
𝛽CD, efferocytosis was reduced, suggesting a requirement of
LR integrity for ingestion of AC. Structures like LR permit
receptors with a nontransducing short intracytoplasmic
portion, like CD36, to come into close proximity with other
receptors promoting interactions that allow signalling. These
results show that efferocytosis increases the colocalisation of
PAFR and CD36 in the macrophage plasma membrane, and
that this colocalisation probably happens in the same LR.
Although there must be other receptors docked in these LR,
these data strongly suggest that PAFR and CD36 interact to
achieve optimal efferocytosis.
Regulatory macrophages can be generated by several
stimuli such as Fc𝛾 and toll-like receptor ligands, glucocorti-
coids, prostaglandins, and apoptotic cells [2, 3, 25].Themajor
feature of regulatory macrophages is their anti-inflammatory
ability due to the production of high levels of IL-10, a potent
cytokine with inhibitory effect on immune response, and
low levels of IL-12, which has an effect that is opposite to
that of IL-10. The balance of IL-10 and IL-12 production
has been previously employed to establish the polarisation
of macrophage phenotype [5, 26, 27]. We showed here that
phagocytosis of apoptotic cells induces more IL-10 than IL-
12p40. When macrophages that have ingested apoptotic cells
were stimulated with LPS, they produced significantly higher
levels of IL-10 than those that had not been exposed to
apoptotic cells. This was not observed with IL-12, where the
increased levels induced by LPSwere not further increased by
the phagocytosis of apoptotic cells. Phagocytosis of apoptotic
cells by human macrophages even decreased the production
of IL-12p70 induced by LPS and IFN-𝛾, as described by Kim
et al. [28]. This difference may be explained by the following:
they used human macrophages and we used bone marrow-
derived murine macrophages; they activated the cells with
LPS plus IFN-𝛾 and we used only LPS; and they measured
the subunit p70 of IL-12, whereas in our case we used p40. In
our study, the ratio between IL-10 and IL-12 was increased by
efferocytosis, leading to the IL-10high/IL-12p40low phenotype,
which is characteristic of regulatory macrophages. Moreover,
this enhancement of the IL-10/IL-12 ratio was dependent
on both PAFR and CD36 engagement, suggesting that both
receptors are involved in macrophage polarisation towards a
regulatory phenotype.
In a previous study, we observed that the injection of
a subtumorigenic dose of melanoma cells together with
apoptotic cells promoted tumour growth and that PAFR
antagonists prevented this effect [7]. This suggests that
PAFR antagonists, by inhibiting AC recognition, can prevent
macrophages from acquiring the regulatory phenotype; and
thus the blocking of PAFR during tumour growth could be of
therapeutic interest. Another consequence of blocking PAFR
is the potential reduction of foam cell formation due to the
inhibition of oxLDL uptake, which would be theoretically
desirable in atherosclerosis [13, 14]. On the other hand, we
showed here that blocking PAFR and/or CD36 reduces the
clearance of apoptotic cells, which is an essential mechanism
for maintaining homeostasis. The defective clearance of
apoptotic cells was associated with some autoimmune and
chronic diseases such as systemic lupus erythematosus, type 1
diabetes, chronic obstructive pulmonary disease, and cardio-
vascular disease [1]. Clearly, the use of agents that block these
receptors should be considered with great care. Moreover,
some authors propose regulatory macrophages to be used in
protocols for immunomodulation to treat inflammatory and
autoimmune diseases [29, 30]. In this case, pretreatment of
macrophages with ligands of PAFR and/or CD36 might be
useful and may increase their drift towards the regulatory
phenotype. The present study added to the knowledge of the
mechanisms involved in efferocytosis. It would be desirable to
further unravel thesemechanisms,with the aimof identifying
strategies to treat diseases caused by defective efferocytosis
and treatments based on immunomodulatory macrophages.
5. Conclusion
It can be concluded that the phagocytosis of apoptotic
cells engages CD36 and PAFR, possibly in lipid rafts, and
this is required for optimal efferocytosis and the establish-
ment of the macrophage regulatory phenotype (IL-10high/IL-
12p40low).
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